title: The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis.
abstract: Conclusive evidence regarding the effect of statins on non-end stage chronic kidney disease (CKD) has not been reported previously. This meta-analysis evaluated the association between statins and microalbuminuria, proteinuria, progression, and all-cause mortality in patients with non-end stage CKD. Databases (e.g., PubMed, Embase and the Cochrane Library) were searched for randomized controlled trials (RCTs) with data on statins, microalbuminuria, proteinuria, renal health endpoints, and all-cause mortality patients with non-end stage CKD to perform this meta-analysis. The mean difference (MD) of the urine albumin excretion ratios (UAER), 24-h urine protein excretion, and risk ratios (RR) of all-cause mortality and renal health endpoints were calculated, and the results are presented with 95% confidence intervals (CI). A total of 23 RCTs with 39,419 participants were selected. The analysis demonstrated that statins statistically reduced UAER to 26.73 μg/min [95%CI (-51.04, -2.43), Z=2.16, P<0.05], 24-h urine protein excretion to 682.68 mg [95%CI (-886.72, -478.63), Z=6.56, P<0.01] and decreased all-cause mortality [RR=0.78, 95%CI (0.72, 0.84), Z=6.08, P<0.01]. However, the analysis results did not indicate that statins reduced the events of renal health endpoints [RR=0.96, 95%CI (0.91,1.01), Z=1.40, P>0.05]. In summary, our study indicates that statins statistically reduced microalbuminuria, proteinuria, and clinical deaths, but statins did not effectively slow the clinical progression of non-end stage CKD.
authors.affiliation: Department of Cardiology, the Second People's Hospital of Foshan (the Affiliated Hospital at Foshan, Southern Medical University), Foshan, PR China. Electronic address: dede-308@163.com.
authors.forename: Zhenhong
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou 510515, PR China. Electronic address: wupingsheng123@aliyun.com.
authors.forename: Pingsheng
authors.initials: P
authors.lastname: Wu
authors.affiliation: Department of Cardiology, the Second People's Hospital of Foshan (the Affiliated Hospital at Foshan, Southern Medical University), Foshan, PR China.
authors.forename: Jiping
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, the Second People's Hospital of Foshan (the Affiliated Hospital at Foshan, Southern Medical University), Foshan, PR China.
authors.forename: Shunyin
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Cardiology, the Second People's Hospital of Foshan (the Affiliated Hospital at Foshan, Southern Medical University), Foshan, PR China.
authors.forename: Gengxin
authors.initials: G
authors.lastname: Zhang
mesh_terms: D000419:Albuminuria / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D018450:Disease Progression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: All-cause mortality; Meta-analysis; Microalbuminuria; Non-end stage chronic kidney disease; Proteinuria; Statins